Fatty Acid Amide HU-671 for Prader-Willi Syndrome Bone Density
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with Prader-Willi syndrome suffer from reduced bone mineral density and increased risk of osteoporosis due to impaired bone remodeling, which existing treatments have not adequately addressed.
Innovation Solution
Administration of a therapeutically effective amount of a fatty acid amide of an amino acid, such as oleoyl α-methyl-serine (HU-671), which inhibits bone resorption and promotes bone deposition, thereby increasing bone density and strength.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for Prader-Willi syndrome, then other symptoms may be managed, but bone mineral density remains reduced and osteoporosis risk is not adequately addressed
Solution Approach 1:
The patent applies parameter changes by administering compounds that alter the biochemical parameters of bone metabolism. Specifically, the treatment modifies the activity levels of osteoclasts and osteoblasts through pharmacological intervention, changing the balance between bone resorption and bone formation parameters to achieve improved bone mineral density and reduced osteoporosis risk in PWS patients
Solution Approach 2:
The patent employs intermediary substances (compounds of Formula I) that act as mediators between the disrupted bone remodeling process and the desired therapeutic outcome. These compounds serve as biochemical intermediaries that regulate osteoclast and osteoblast activity, bridging the gap between the underlying PWS pathology and the corrective effect on bone health
2Strength
If bone remodeling is impaired in PWS patients, then bone formation is insufficient, but increasing bone formation alone may not address the underlying resorption imbalance
Solution Approach 1:
The patent applies the extraction principle by specifically targeting and addressing the bone resorption component of the imbalance. The treatment extracts or isolates the resorption problem from the overall bone remodeling process by using compounds that selectively inhibit osteoclast activity, thereby removing the harmful resorption effect without directly forcing bone formation
Solution Approach 2:
The patent changes the parameters of both bone formation and bone resorption simultaneously. The compounds of Formula I modify the kinetic parameters of osteoclast-mediated resorption and osteoblast-mediated formation, adjusting both rates to achieve a new equilibrium that favors net bone gain and improved bone quality in PWS patients
Data Source
AI summary
The present disclosure provides pharmaceutical compositions comprising a fatty acid amide of an amino acid as defined herein, such as oleoyl-α-methyl-serine, or a stereoisomer or salt thereof, for improving, as in increasing or preventing loss of, bone mineral density and/or treating osteoporosis in patients suffering from Prader-Willi syndrome; and their methods of use.